Response

To the Editor:
We would like to sincerely thank Dr Khurana for her interest and her comments regarding our article published in CHEST (December 2009). 1 Dr Khurana suggested that the patient's current disease should be better attributed to an etanercept side effect, rather than to a second primary disease (meaning sarcoidosis) in a patient diagnosed with rheumatoid arthritis. Although the suggestions made by our colleague are reasonable, certain remarks should be made.
In the article by Daïen et al, 2 all drug-induced granulomatous disease developed during etanercept treatment and mean delay times for disease to present (26 months for etanercept and 51 months for infl iximab) were under continuous anti-tumor necrosis factor (TNF) treatment. Our patient had been off any treatment with anti-TNF for . 5 years. Even if we hypothesize that her disease was present and asymptomatic all that time, it should have normally already subsided. In the article by Daïen et al, 2 all cases resolved within 1 year of drug withdrawal. Therefore, the clinical course of this patient does not support a drug-induced reaction.
For these reasons, it is unlikely that etanercept was the cause in our patient; the option of a second primary disease (meaning sarcoidosis) seems much more reasonable. Etanercept side effects, though, are not fully elucidated. Although late development of pulmonary fi brosis may occur after chest irradiation or certain drugs, this has not been demonstrated for granulomatous lung disease and anti-TNF medication. 
